Table 2.
Adverse Events of Panobinostat31
| Incidence* All Grades (Grade 3/4) |
|
|---|---|
| Hematologic | |
| Thrombocytopenia | 98% (68%) |
| Lymphopenia | 83% (54%) |
| Leukopenia | 81% (24%) |
| Neutropenia | 75% (35%) |
| Anemia | 62% (18) |
| Non-Hematologic Laboratory | |
| Hyperbilirubinemia | 21% (1%) |
| Hypophosphatemia | 64% (20%) |
| Hyponatremia | 49% (13%) |
| Elevated serum creatinine | 41% (1%) |
| Diarrhea | 68% (25%) |
| Fatigue | 57% (24%) |
| Nausea | 36% (5%) |
| Vomiting | 26% (7%) |
| Decreased appetite | 28% (3%) |
| Peripheral edema | 29% (2%) |
| Pyrexia | 26% (1%) |
| ST-segment depression | 22% |
| T-wave abnormalities | 40% |
Note:
*
Side effects reported in combination with bortezomib and dexamethasone. Reprinted from Lancet Oncol, 15/11, San-Miguel JF, Hungria VT, Yoon SS, et al, Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial,1195–1206, Copyright (2014), with permission from Elsevier.